- Home
- SENS vs ACTU Comparison
SENS vs ACTU Comparison
Compare SENS & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENS
- ACTU
- Stock Information
- Founded
- SENS 1996
- ACTU 2015
- Country
- SENS United States
- ACTU United States
- Employees
- SENS N/A
- ACTU N/A
- Industry
- SENS Industrial Machinery/Components
- ACTU
- Sector
- SENS Industrials
- ACTU
- Exchange
- SENS Nasdaq
- ACTU NYSE
- Market Cap
- SENS 167.8M
- ACTU 153.1M
- IPO Year
- SENS N/A
- ACTU 2024
- Fundamental
- Price
- SENS $0.28
- ACTU $8.68
- Analyst Decision
- SENS Strong Buy
- ACTU
- Analyst Count
- SENS 1
- ACTU 0
- Target Price
- SENS $2.00
- ACTU N/A
- AVG Volume (30 Days)
- SENS 4.7M
- ACTU 57.4K
- Earning Date
- SENS 11-07-2024
- ACTU 11-13-2024
- Dividend Yield
- SENS N/A
- ACTU N/A
- EPS Growth
- SENS N/A
- ACTU N/A
- EPS
- SENS N/A
- ACTU N/A
- Revenue
- SENS $22,205,000.00
- ACTU N/A
- Revenue This Year
- SENS $1.05
- ACTU N/A
- Revenue Next Year
- SENS $61.23
- ACTU N/A
- P/E Ratio
- SENS N/A
- ACTU N/A
- Revenue Growth
- SENS 11.41
- ACTU N/A
- 52 Week Low
- SENS $0.28
- ACTU $5.51
- 52 Week High
- SENS $0.75
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- SENS 32.58
- ACTU N/A
- Support Level
- SENS $0.28
- ACTU N/A
- Resistance Level
- SENS $0.36
- ACTU N/A
- Average True Range (ATR)
- SENS 0.02
- ACTU 0.00
- MACD
- SENS -0.01
- ACTU 0.00
- Stochastic Oscillator
- SENS 6.91
- ACTU 0.00
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.